These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26198373)

  • 1. Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer.
    Sjøblom B; Grønberg BH; Benth JŠ; Baracos VE; Fløtten Ø; Hjermstad MJ; Aass N; Jordhøy M
    Lung Cancer; 2015 Oct; 90(1):85-91. PubMed ID: 26198373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer.
    Sjøblom B; Benth JŠ; Grønberg BH; Baracos VE; Sawyer MB; Fløtten Ø; Hjermstad MJ; Aass N; Jordhøy M
    Clin Lung Cancer; 2017 Mar; 18(2):e129-e136. PubMed ID: 27825639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial.
    Laack E; Mende T; Dürk H; Kneba M; Dickgreber N; Welte T; Müller T; Scholtze J; Graeven U; Jasiewicz Y; Edler L; Hossfeld DK
    Eur J Cancer; 2002 Mar; 38(5):654-60. PubMed ID: 11916547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer.
    Lorusso V; Crucitta E; Panza N; Silvestris N; Guida M; Carpagnano F; Mancarella S; Sambiasi D; De Lena M
    Ann Oncol; 2002 Dec; 13(12):1862-7. PubMed ID: 12453853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
    Martoni A; Marino A; Sperandi F; Giaquinta S; Di Fabio F; Melotti B; Guaraldi M; Palomba G; Preti P; Petralia A; Artioli F; Picece V; Farris A; Mantovani L
    Eur J Cancer; 2005 Jan; 41(1):81-92. PubMed ID: 15617993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
    Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS
    Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older.
    Chen YM; Perng RP; Chen MC; Tsai CM; Ming-Liu J; Whang-Peng J
    Lung Cancer; 2003 May; 40(2):221-6. PubMed ID: 12711125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer.
    Chen YM; Perng RP; Yang KY; Liu TW; Tsai CM; Ming-Liu J; Whang-Peng J
    Chest; 2000 Jun; 117(6):1583-9. PubMed ID: 10858387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group.
    Laack E; Dickgreber N; Müller T; Knuth A; Benk J; Lorenz C; Gieseler F; Dürk H; Engel-Riedel W; Dalhoff K; Kortsik C; Graeven U; Burk M; Dierlamm T; Welte T; Burkholder I; Edler L; Hossfeld DK;
    J Clin Oncol; 2004 Jun; 22(12):2348-56. PubMed ID: 15197195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
    Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
    Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine, ifosfamide and vinorelbine in advanced non-small cell lung cancer: a phase II study.
    Recchia F; Lombardo M; De Filippis S; Rosselli M; Rea S
    Anticancer Res; 2002; 22(2B):1321-8. PubMed ID: 12168945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group.
    Fløtten Ø; Grønberg BH; Bremnes R; Amundsen T; Sundstrøm S; Rolke H; Hornslien K; Wentzel-Larsen T; Aasebø U; von Plessen C
    Br J Cancer; 2012 Jul; 107(3):442-7. PubMed ID: 22759880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
    Argiris A; Liptay M; LaCombe M; Marymont M; Kies MS; Sundaresan S; Masters G
    Lung Cancer; 2004 Aug; 45(2):243-53. PubMed ID: 15246197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer.
    Barón F; Cueva J; Graña B; Curiel T; León L; Vázquez F; Candamio S; López R
    Eur J Cancer; 2001 Jul; 37(11):1381-4. PubMed ID: 11435068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
    Kosmas C; Tsavaris N; Panopoulos C; Vadiaka M; Stavroyianni N; Kourelis T; Malamos N; Antonopoulos M; Kalofonos HP
    Eur J Cancer; 2001 May; 37(8):972-8. PubMed ID: 11334721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
    Saito H; Nakagawa K; Takeda K; Iwamoto Y; Ando M; Maeda M; Katakami N; Nakano T; Kurata T; Fukuoka M
    Am J Clin Oncol; 2012 Feb; 35(1):58-63. PubMed ID: 21293243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial.
    Herbst RS; Lynch C; Vasconcelles M; Teicher BA; Strauss G; Elias A; Anderson I; Zacarola P; Dang NH; Leong T; Salgia R; Skarin AT
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):151-9. PubMed ID: 11561781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial.
    Laack E; Mende T; Benk J; Chemaissani A; Scholtze J; Lorenz C; Niestroy A; Dalhoff K; Müller T; Walter T; Dürk H; Edler L; Hossfeld DK
    Eur J Cancer; 2001 Mar; 37(5):583-90. PubMed ID: 11290433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.